Home | EndoTODAY | EndoATLAS

Beginner | ESA | Schedule | OPD

Seminars | Atlas | Recent | Links

EndoTODAY ³»½Ã°æ ±³½Ç


[SMC Monday GI conference 2017-3-20. Immunotherapy for HCC]

Previous | Next

Immunotherapy for HCC (°­¿ø¼® ±³¼ö´Ô Ư°­)

Basic concepts of immunotherapy

T cell activation is a multiple-signal process

Tumors can express co-inhibitory ligands.

The era of immunotherapy

ÇöÀç´Â melanoma, NSCLC µî¿¡¼­ FDA ½ÂÀÎÀ» ¹Þ¾Ò½À´Ï´Ù.

º´¼Ò ÁÖº¯¿¡ T cell inflammationÀÌ ÀÖ¾î¾ß ÇÑ´Ù. Immune desert¿¡¼­´Â È¿°ú°¡ ¾øÀ» °ÍÀδÙ. Tumor¿¡¼­ PD-L1ÀÌ ¾øÀ¸¸é È¿°ú°¡ ¾øÀ» °ÍÀÌ´Ù. µ¿¹Ý ¸¶Ä¿°¡ response ¿¹Ãø¿¡ ±×´ÙÁö È¿°ú°¡ ¾ø¾ú´Ù.



© ÀÏ¿ø³»½Ã°æ±³½Ç ¹Ù¸¥³»½Ã°æ¿¬±¸¼Ò ÀÌÁØÇà. EndoTODAY Endoscopy Learning Center. Lee Jun Haeng.